Skip to Content
Søg Menu

Danish and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostatacancer

Mirikizumab Improves Fatigue Abdominal Pain and Stool Frequency in Crohn’s Disease

/ Jan Andreasen
CrohnUEGW25

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
ESMO25Blærecancer

Possible Biomarkers for Progression Independent of Relapse Activity Identified in RMS

/ Jan Andreasen
ECTRIMS25

Cladribine Shows a Robust Safety Profile – Both as First-Line and Subsequent Therapy in MS

/ Jan Andreasen
ECTRIMS25MS

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

/ Alicia Morgans / Jan Andreasen
ESMO25Prostatacancer
Back to top